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Summary
Objective: Osteoarthritis (OA) is the most common of all joint diseases, but the molecular basis of its onset and progression is controversial.
Several studies have shown that modiﬁcations of N-glycans contribute to pathogenesis. However, little attention has been paid to N-glycan
modiﬁcations seen in articular cartilage. The goal of this study was to identify disease speciﬁc N-glycan expression proﬁles in degenerated
cartilage in a rabbit OA model induced by anterior cruciate ligament transection (ACLT).
Methods: Cartilage samples were harvested at 7, 10, 14, and 28 days after ACLT and assessed for cartilage degeneration and alteration in N-
glycans. N-Glycans from cartilage were analyzed by high performance liquid chromatography and mass spectrometry.
Results: Histological analysis showed that osteoarthritic changes in cartilage occurred 10 days after ACLT. Apparent alterations in the N-gly-
can peak pattern in cartilage samples were observed 7 days after ACLT, and overall N-glycan changes in OA reﬂected alterations in both
sialylation and fucosylation. These changes apparently preceded histological changes in cartilage.
Conclusion: These results indicate that changes in the expression of N-glycans are correlated with OA in an animal model. Understanding
mechanisms underlying changes in N-glycans seen in OA may be of therapeutic value in treating cartilage deterioration.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Chondrocyte metabolism is controlled by genetic and
environmental factors, such as extracellular matrix (ECM)
composition, soluble mediators, or mechanical factors1,2.
Osteoarthritis (OA), which results from a breakdown in the
balance of these factors, is the most common joint disease.
To date, numerous studies have investigated its pathogene-
sis1e8. However, factors mediating onset and aggravation
of OA are still controversial.
Glycobiology, deﬁned as the analysis of biological func-
tion of sugar chains covalently bound to proteins and lipids,
has been recently applied to molecular-based investiga-
tions9. Sugar chains attached to proteins (glycoproteins)
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772Glycoprotein glycans are found on the cell surface, in the
ECM, and in serum. These glycans act as an interface on
the cell surface and modulate protein properties, including
folding, secretion, targeting, and protease resistance10,11.
Several studies show that glycan modiﬁcations of proteins
contribute to the pathogenesis of some diseases12,13. One
characteristic of cartilage is that some chondrocytes reside
in areas rich in ECM. In addition, it is well known that glyco-
proteins are abundant on the cell surface and in cartilage
ECM. These observations lead to a working hypothesis
that sugars attached to proteins contribute to chondrocyte
metabolism.
Glycans attached to proteins are classiﬁed into two
groups: glycans attached to an asparagine residue through
a nitrogen atom (N-glycans) and those attached to a serine
or threonine oxygen (O-glycans)11. Both types have been in-
tensively studied, and many studies report structural and
functional analyses of N-glycans14. Based on these data,
a relationship between N-glycan alteration and disease
has recently been emerged12,13,15e18. For example, several
studies of N-glycans of serum immunoglobulin G (IgG) mol-
ecules associated with the rheumatoid arthritis (RA) indicate
that changing N-glycan structure contributes to RA19e21.
However, little attention has been paid to N-glycan alter-
ations occurring in articular cartilage in a diseased condition.
Glycans have ﬁve major functions: (1) providing cell wall
and ECM structural components, (2) modifying protein
773Osteoarthritis and Cartilage Vol. 16, No. 7properties, (3) directing glycoconjugates, (4) mediating and
modulating cell adhesion, and (5) mediating and modulating
signaling. Thus, we hypothesized that cartilage N-glycans
would be altered in parallel with cartilage degradation in
OA and would vary according to the degree of deterioration.
Particularly, N-glycan alterations should occur at early
phases of OA aggravation. To test this hypothesis, we ana-
lyzed N-Glycans of rabbit OA cartilage explants induced by
anterior cruciate ligament transection (ACLT). The speciﬁc
aims of this study were to clarify the alterations in cartilage
N-glycans with OA aggravation and to identify N-glycan
structures correlated with cartilage deterioration.Materials and methodsANIMALS AND SURGICAL PROCEDURESSeventy-eight adult female Japanese white rabbits (15e16-week-old)
weighing 2.6e3.1 kg purchased from a professional breeder (Japan SLC,
Inc., Hamamatsu, Japan) were used for this study according to the estab-
lished ethical guidelines approved by the local animal care committee.
Rabbits were anesthetized with 0.6 ml pentobarbital sodium (50 mg/ml)
injections and then maintained on isoﬂurane. To induce osteoarthritic
changes of articular cartilage, the right knee ACL was sectioned through
a medial parapatellar incision (OA group). As a sham control, arthrotomy
without ACLT was performed in sham group. Rabbits were housed in plastic
cages and allowed to move freely after the operation. At days 0, 7, 10, 14,
and 28, animals were euthanized by an intravenous injection of overdose
pentobarbital to obtain cartilage samples for histological and glycostructural
analyses. Serum samples were harvested prior to euthanasia. Here, day 7 is
deﬁned as 7 days after the operation, and day 0 means the day prior to the
operation.HISTOLOGICAL ANALYSIS (N¼ 36)
To determine osteoarthritic changes in OA and sham groups, cartilage
samples (n¼ 4) were analyzed histologically at days 0, 7, 10, 14, and 28.
Each sample, including the tibial plateau and femoral condyle, was ﬁxed in
10% neutral buffered formalin. Tissue blocks were decalciﬁed with 14% eth-
ylenediaminetetraacetic acid (EDTA), cut in a sagittal plane, and stained with
hematoxylin and eosin (HE) and Safranin Oefast green. To avoid observer
bias, slides were coded prior to microscopic analysis. Osteoarthritic changes
in each sample were quantiﬁed using the modiﬁed Mankin score22.PREPARATION OF PYRIDYLAMINATED (PA)-N-GLYCAN (N¼ 42)
Cartilage samples of the tibial plateau and serum were obtained from
each animal at days 0, 7, 10, and 28. Cartilage minced by a razor and serum
was heated to 90C for 15 min. After lyophilization, each sample was di-
gested sequentially with trypsin, chymotrypsin, N-glycosidase F, and pro-
nase as described23. N-Glycan fractions were puriﬁed on a gel-ﬁltration
column (Bio-Gel P-4, 1 38 cm, water, Nippon Bio-Rad Laboratories KK,
Tokyo, Japan), and tagged by ﬂuorescent labeling using 2-aminopyridine
to increase sensitivity for analysis24. Excess reagents were removed by
gel-ﬁltration on Sephadex-G-15 (Amersham Bioscience, Tokyo, Japan).
PA-N-glycans were analyzed using high performance liquid chromatography
(HPLC) and mass spectrometry (MS).HPLC ANALYSISHPLC analysis using the L-7000 HPLC system (Hitachi High-Technolo-
gies, Tokyo, Japan) was performed under conditions previously de-
scribed25,34,36. PA-N-glycans were separated on an octadecylsilica (ODS)
column (HRC-ODS, 6 150 mm, Shimadzu, Kyoto, Japan), and each
peak on the ODS column was applied individually to an amide column
(TSK-gel Amide-80, 4.6 250 mm, Tosoh, Tokyo, Japan). The relative
amount of PA-N-glycans was calculated based on the peak area analyzed
by attached software on the HPLC system. Elution positions of PA-N-glycan
on the ODS and amide columns were converted to glucose units (GU),
which corresponded to relative degree of polymerization of a1,6-glucose ol-
igosaccharides, for increasing reproducibility. N-Glycan structures were sug-
gested by comparing elution positions with data reported in the same
analytical conditions, and conﬁrmed with further HPLC analysis combined
with partial digestion, and/or MS. Elution positions and code numbers of
approximately 500 kinds of oligosaccharide are described in thesereferences34,35. The validity of the elution positions and partial digestions
was conﬁrmed using well-known standard PA-N-glycans and previous
studies27,36.
N-Glycans can form various structures, but have a common core struc-
ture and some rules in linkages11. To determine the detailed N-glycans’
structure related to OA, PA-N-glycans were digested sequentially with
b-N-acetylhexosaminidase (HexNAcase, Jack bean, Seikagaku Co., Tokyo,
Japan) which removed b-linked GalNAc and GlcNAc, a1,3/4-fucosidase (a3/
4-Fase, Takara Co., Shiga, Japan) and weak hydrochloric acid to hydrolyze
sialic acids. After each digestion, PA-N-glycans were individually analyzed
by HPLC on both columns to conﬁrm elution positions23,25.MSTo identify the PA-N-glycan structure, some PA-N-glycans separated by
HPLC were further analyzed by matrix-assisted laser desorption/ionization
time-of-ﬂight MS (MALDI-TOF MS) using an Ultraﬂex TOF/TOF mass spec-
trometer (Bruker Daltonics GmbH, Bremen, Germany). As matrices, 2,5-de-
hydroxybenzoic acid (DHB) and a-cyano-4-hydroxycinnaminic acid (CHCA)
were used. PA-N-glycans fractionated on HPLC were dissolved and applied
to MALDI-TOF MS as described26. Based on results from HPLC and MS,
each precise N-glycan structure was determined.
All measurements were performed using an Ultraﬂex TOF/TOF mass
spectrometer equipped with a reﬂector and controlled by the FlexControl
2.2 software package (Bruker Daltonics). In MALDI-TOF MS reﬂector
mode, ions generated by a pulsed UV laser beam (nitrogen laser,
l¼ 337 nm, 5 Hz) were accelerated to a kinetic energy of 23.5 kV. Meta-
stable ions generated by laser-induced decomposition of the selected pre-
cursor ions were analyzed without any additional collision gas. In MALDI-
LIFT-TOF/TOF mode, precursor ions were accelerated to 8 kV and se-
lected in a timed ion gate. The fragments were further accelerated by
19 kV in the LIFT cell (LIFT indicates ‘‘lifting’’ the potential energy for
the second acceleration of ion source), and their masses were analyzed
after the ion reﬂector passage. Masses were automatically annotated by
using the FlexAnalysis 2.2 software package. External calibration of
MALDI mass spectra was carried out using singly charged monoisotopic
peaks of a peptide mixture of human angiotensin II (m/z 1046.542), bomb-
esin (m/z 1619.823), ACTH-(18e39) (m/z 2465.199), and somatostatin 28
(m/z 3147.472).STATISTICAL ANALYSISData were represented as means standard deviation (SD). Signiﬁcant
differences between groups were assessed by unpaired t tests. P-values
of less than 0.05 were considered signiﬁcant.ResultsHISTOLOGICAL FINDINGSAfter the operations, rabbits exhibited a normal gait pat-
tern by footprint analysis (data not shown). Also, infec-
tions were not seen macroscopically in any knee joint
(data not shown). At day 7, no histological changes of
the tibial plateau were seen in HE-stained samples of
the OA group [Fig. 1(b)]. Samples evaluated at day 10
showed common OA changes, including deterioration of
the superﬁcial cartilage layer and a reduced number of
chondrocytes in superﬁcial and middle cartilage layers
[Fig. 1(c)]. At day 28, a reduced number of chondrocytes
were observed in whole layers [Fig. 1(e)], and cloning of
chondrocytes was apparent in these damaged areas
[Fig. 1(e)]. While Safranin Oefast green staining showed
no signiﬁcant change from day 7 to day 14 [Fig. 1(gei)],
both showed signiﬁcant reduction at day 28 [Fig. 1(j)]. In
the sham group, from day 7 to day 28 no histological in-
dications of OA changes were observed in any samples
(data not shown). Histological changes of the femoral
condyle were observed later than histological changes
of the tibial plateau (data not shown). After day 10,
mean histological scores of the tibial plateau were signif-
icantly higher in the OA group than in the sham group
(3.6 0.5 vs 2.3 0.5 at day 10, P< 0.05; 7.0 0.6 vs
2.4 0.4 at day 28, P< 0.05, Fig. 2).
Fig. 1. Histology of cartilage after ACLT in medial tibial plateau in the rabbit knee joint. (aee) HE-stained sections. (fej) Safranin
O-fast green stained sections. (a) Control articular cartilage shows a smooth surface. (b) At day 7, no signiﬁcant changes compared with con-
trol cartilage were observed. (c) At day 10, superﬁcial diffuse loss of chondrocytes (*) with surface irregularity was observed. (d) At day 14,
diffuse loss of chondrocytes from superﬁcial and middle zones (*) with surface irregularity was observed. (e) At day 28, diffuse loss of chon-
drocytes in the whole zone with clone formation (solid arrow) was observed. (f) Control articular cartilage with Safranin O-fast green stain. (gei)
At days 7,10, and14, no signiﬁcant change of Safranin O-fast green staining was observed. (j) At day 28, severe loss of Safranin Oefast green
staining and clefts (empty arrow) was observed.
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pattern of serum from day 7 to day 28 in the OA group
(Fig. 3). In cartilage analysis, there were no apparent alter-
ations in the N-glycan peak pattern from day 7 to day 28 in
the sham group. By contrast, signiﬁcant alterations in the
N-glycan peak pattern in cartilage were observed in the
OA group from day 7 postoperatively (Fig. 4). Alterations
in peak shape suggested a change in the composition of
N-glycans contained in the peak. To conﬁrm this, we puriﬁed
peaks by HPLC on an ODS column and analyzed each on
an amide column in a different chromatographic mode.
Each altered peak on the ODS column was separated into
three peaks on the amide column, referred to as N-glycan
A (a), B (b), and C (c) in the order of separation time






























Fig. 2. Histological scores of medial tibial plateau. Values are
meansSD. Shown are scores for histological parameters with
comparisons between groups. Histological analysis revealed that
slightly degenerative changes in cartilage occurred in all cases
starting 10 days after ACLT. *Denotes statistical signiﬁcance
(P < 0.05) vs sham group. #Denotes statistical signiﬁcance
(P< 0.05) vs control.of N-glycan A in the OA group signiﬁcantly decreased from
day 7 to day 28 compared to the sham group (40.6 1.80
vs 36.0 1.40 at day 7, P< 0.05; 39.8 1.54 vs
35.6 1.97 at day 28, P< 0.05, Fig. 5), while the value of
N-glycan C in the OA group signiﬁcantly increased from
day 7 compared to the sham group (44.7 1.91 vs
40.8 1.28 at day 7, P< 0.05; 46.0 2.67 vs 40.2 1.03
at day 28, P< 0.05, Fig. 5). The mean ratio of N-glycan B
did not signiﬁcantly change (data not shown). Themean ratio
of N-glycans AeC after day 7 was signiﬁcantly higher in the
OA group than in the sham group (1.25 0.11 vs
1.01 0.04 at day 7, P< 0.05; 1.32 0.11 vs 1.01 0.04
at day 28, P< 0.05, Fig. 5).Fig. 3. Chromatograms of PA-N-glycans obtained from rabbit serum
glycoproteins on an ODS column. There were no signiﬁcant alter-
ations in the N-glycan peak pattern of serum from day 7 to day
28 in the OA group compared with controls.
Fig. 4. Chromatograms of PA-N-glycans obtained from rabbit
cartilage glycoproteins on an ODS column. Two peaks (solid ar-
row) in the chart of day 0 and the sham-operated group were
seen as one peak (empty arrow) from day 7 after ACLT. Those
peaks included three peaks on an amide column, referred to as
N-glycan A (a), B (b), and C (c), in the order of separation time (*).
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OSTEOARTHRITIC CHANGESFig. 5. The ratio in the peak area of N-glycans related to OA. Values
are meansSD. The mean ratio of N-glycan A decreased signiﬁ-
cantly from 7 days in the OA group. The mean ratio of N-glycan
C increased signiﬁcantly from 7 days in the OA group. The mean
ratio of N-glycan AeC increased signiﬁcantly from 7 days in the
OA group. *Denotes statistical signiﬁcance (P< 0.05) vs sham
group. #Denotes statistical signiﬁcance (P< 0.05) vs control.MALDI-TOF spectra of N-glycans A and C with DHB as
a matrix indicated a molecular mass of 2239.6 and
2094.6, respectively (Fig. 6). Each MALDI-TOF/TOF spec-
tra showed constituents of N-glycans A and C (Fig. 7).
MALDI-TOF and TOF/TOF spectra of N-glycans with
CHCA as a different matrix indicated almost the same
mass fragmentation compared with DHB (data not shown).
Molecular mass of 2239.6 and 2094.6 corresponds with
a protonated PA-glycan which consists of 3 Hex, 6 HexNAc
and N-acetylneuraminic acid (NANA); and 3 Hex, 6 HexNAc
and Fuc, respectively. These compositions and abundant
fragment peaks of di-HexNAc (406.9 and 407.1) and peaks
devoid of di-HexNAc, 1542.1 and 1542.2, indicate these N-
glycans which include GalNAceGlcNAc units instead of
GaleGlcNAc units in their outer arms. After sequential par-
tial digestion, elution positions of both N-glycans on the
two-dimensional map coincided with 110.4a GalNAcb1,
4-GlcNAcb1,2-Mana1,3-(Mana1,6-)Manb1,4-GlcNAcb1,4-
(Fuca1,6-)GlcNAc which conﬁrmed from a previous study
combining HPLC, NMR and methylation analyses31. The
elution position on the amide column was smaller than the
one of a similar structure, 110.4, which includes Gal-
b1,4eGlcNAc units in their outer arms25. Based on these
results, the ﬁnal form of N-glycan digested partially was
assigned as 110.4a, and elution positions and suggested
structures of digested N-glycans A and C are shown in
Fig. 8. This indicated that NANA of N-glycan A and Fuc of
N-glycan C was attached to the same a3Man branch of
the outer arm and di-HexNAc is GalNAcb1,4eGlcNAc31.
The NANA to GalNAc linkage was determined to be a2,6
based on an observed reduction in GU on the amide col-
umn27. a2,3 NeuAc was reduced to about 0.5 GU on the
amide column; on the other hand a2,6 NeuAc increased
by about 0.2 GU on the amide column according to the
two-dimensional mapping technique32,33. The linkage of
Fuc in the outer arm of N-glycan C was determined to bean a1,3 linkage to GlcNAc because it was digested with
a3/4-Fase and the GalNAc bound to 4 position of GlcNAc.
Changing of elution positions with partial digestion is al-
ready conﬁrmed in a previous report32,33. In this way, struc-
tures of N-glycans A and C were ﬁnally determined as in
Fig. 9.Discussion
The goal of this study was to determine potential alter-
ations in cartilage N-glycans with aggravated OA. We ﬁrst
showed alterations in the N-glycan peak pattern of articular
cartilage between normal rabbit cartilage (sham group)
and OA cartilage induced by ACLT (OA group). Then, by
comparing peaks obtained from both groups, we showed
that the composition of cartilage N-glycans was signiﬁcantly
altered in the OA group prior to apparent histological
changes. This observation indicates that N-glycan alter-
ations in cartilage occur at very early phases of OA
aggravation. It is well known that alterations in N-glycans
are associated with speciﬁc disease-related mecha-
nisms12,13,15. Several studies of rheumatic diseases report
Fig. 6. MALDI-TOF mass spectra. Mass spectrometric analysis of
N-glycans A and C by the MALDI-TOF/TOF method using DHB
as a matrix.
Fig. 8. Structural characterization of N-glycans A and C by a
combination of exoglycosidase digestion and two-dimensional
mapping. A portion of N-glycans A and C was digested with exogly-
cosidases. The elution times on ODS and amide-silica columns of
N-glycans and their exoglycosidase digests are plotted on a two-
dimensional sugar map (expressed as GU). Arrows indicate the
direction of changes in the coordinates of N-glycans A and C after
digestion with: / b-N-acetylhexosaminidase, a1,3/4-fucosi-
dase, weak acid lysis.
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ever, little attention has been given to similar alterations in
articular cartilage. OA, a chronic degenerative joint disease
characterized by articular cartilage deterioration and dam-
age to subchondral bone, is a major cause of disabilities af-
fecting patients’ daily activities. Unlike RA, OA is primarily
considered a local disease caused by abnormal loading on
the articular cartilage. Therefore, analysis of cartilage N-gly-
cans may facilitate the understanding of OA pathogenesis.
To our knowledge, this is the ﬁrst study to determine the
structure of cartilage N-glycans and show alterations in the
composition of the cartilage N-glycans with OA aggravation.
In early stages of OA aggravation, the macromolecular
structure of the ECM is disrupted5. Early in this process,
chondrocytes begin secreting enzymes that can disrupt
ECM macromolecules1,2. In particular these enzymes de-
crease proteoglycan aggregation and concentration ofFig. 7. MALDI-TOF/TOF mass spectra. Structural analysis of
N-glycans A and C by the MALDI-TOF/TOF method using DHB
as a matrix. Structures of fragments of N-glycan in each peak are
indicated. Mannose, B; Fuc, 6; GalNAc, -; GlcNAc, ,; NANA,
A; PA, .cartilage ECM, and their release is accompanied by an
increased rate of chondrocyte apoptosis in areas of carti-
lage regeneration. Our analysis indicates that cartilage
N-glycans undergo changes in the early phases of OA
aggravation. N-glycans are abundant on the cell surface
and in the ECM, and they commonly interact with protein
receptors known as lectins. Through this interaction,
N-glycans mediate cellecell and celleECM interactions
and intra- and extracellular signaling. The current study
showed alteration in the representation of two kinds of
N-glycan whose branch has sialic acid and fucose. Al-
though we suppose that these N-glycans relate to OA initi-
ation or progression in early phase, their biological functions
remain unclear. Further studies will be performed to eluci-
date their functional roles in OA progression. Therefore, al-
terations in the composition of 1A1-210.4b (N-glycan A) and
210.41b (N-glycan C), whose structures are identiﬁed here,
likely play crucial roles in the response of chondrocytes orig. 9. Structure of N-glycans A and C. Indicated are structures of
-glycans related to OA. Mannose, B; Fuc, 6; GalNAc, -;F
NGlcNAc,,; NANA, A; PA .
777Osteoarthritis and Cartilage Vol. 16, No. 7the ECM to changes in the cartilage environment responsi-
ble for initiating OA. Here, we did not identify the localization
of these N-glycans. Future studies are required to deter-
mine the biological roles of N-glycans identiﬁed here in
early phases of OA. We observed no signiﬁcant alterations
in the serum N-glycan pattern with OA aggravation. Watson
et al.20, however, showed alterations in the N-glycan pattern
of serum IgG with rheumatic diseases, including RA, sys-
temic lupus erythematosus, ankylosing spondylitis, Sjo¨g-
ren’s disease, juvenile chronic arthritis, and psoriatic
arthritis. In addition to RA, Parekh et al.21 analyzed the
N-glycan pattern of serum IgG in patients with primary OA
and showed that IgG isolated from patients with primary
OA contained different distributions of bi-antennary com-
plex-type N-glycans. They concluded that primary OA
may be a disease related to changes in intracellular pro-
cessing of N-glycans or in their post-secretory degradation.
Differences between their results and ours may be due to
differences in the N-glycan source, to serum or puriﬁed
IgG, or to mechanisms that induce OA disease. Our current
model is a secondary OA model, in which disease is caused
by joint instability. Pathological changes must be localized
in tissues constituting the joint with cartilage deterioration.
Therefore, we conclude that alterations in the N-glycan pat-
tern occur in cartilage, not in serum. The results obtained
from analysis of both serum and cartilage conﬁrm that OA
aggravation following joint instability mainly results from
local pathogenesis.
These results and analytical methods can now be applied
to clinical studies. The N-glycan pattern of articular cartilage
may be used as a diagnostic indicator of OA or a predictable
indicator of disease aggravation. Although we focus on
early phases of OA aggravation, the N-glycan pattern of ar-
ticular cartilage obtained from rheumatic diseases and at
advanced stages of OA should now be addressed. By com-
paring these results, the utility of the N-glycan pattern as
disease indicators will be established. Also, it is likely that
1A1-210.4b (N-glycan A) and 210.41b (N-glycan C) identi-
ﬁed here play crucial roles in regulating cartilage deteriora-
tion following joint instability, but the localization and
functional roles of these N-glycans are unknown. We are
now determining the identities of proteins with speciﬁc
N-glycan structures. When that analysis is complete, we
will use knock-out or knock-down of either glycosyltransfer-
ase genes or the carrying proteins, followed by a functional
analysis of N-glycans to further analyze their roles in
cartilage deterioration. Finally, the N-glycan pattern likely
depends on species. For this analysis we used rabbit carti-
lage, but N-glycans altered in human OA cartilage may dif-
fer from the N-glycans identiﬁed here. Thus, the N-glycan
pattern of degenerative articular cartilage in humans will
be analyzed in future studies.
Based on results presented here, we predict that
N-glycans of human cartilage will alter with cartilage deteri-
oration in diseases such as OA and RA. We will likely ob-
serve changes in the linkage of saccharides such as sialic
acid and fucose, which is attached to the outer arm of
N-glycan. Complex combinations of glycosyltransferases
and glycosidases control N-glycan composition. Therefore,
further analysis of expression of glycosyltransferases and
glycosidases related to cartilage N-glycans should lead to
elucidation of the pathogenesis of these diseases.
Regarding the biological and biochemical functions of
N-glycans obtained in this study, we cannot study any fur-
ther rabbit model. The reason is that DNA sequences of gly-
cosyltransferases and glycosidases related with cartilage
N-glycans of rabbit are little known. In our future studies,using human cartilages and conditional model mice, we
should determine the functional roles of the N-glycans.
This should lead to a novel strategy for the treatment of OA.
Recent studies suggest that changes in glycosylation, de-
ﬁned as the addition of sugars to proteins and lipids, have
a direct role in the etiology of various diseases, including
congenital disorders of glycosylation, von Willebrand factor
deﬁciency, rheumatic diseases, cancers, and emphyse-
ma12,13,19,20,28e30. Regarding joint diseases, ours is the ﬁrst
study to determine the structure of the cartilage N-glycans
and analyze potential alterations in damaged cartilage
and may provide diagnostics and further insight into OA
pathogenesis.Conﬂict of interest
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